Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.

"Conflict-of-interest disclosure: D.S., I.K., and J.H. received consulting fees from Terumo Blood and Cell Technologies for their participation in the survey creation and interpretation. Outside of the submitted work, J.H. has taken up employment with Vertex Pharmaceuticals subsequent to the work carried out in this article. S.L. is the vice president of the National Alliance of Sickle Cell Centers. S.P. received personal fees for lectures from Novartis and from Celgene for serving on an advisory board; and has received support from Celgene and Vertex Pharmaceuticals for attending meetings. L.H.P. received grants from the National Institutes of Health and the National Heart, Lung, and Blood Institute (K23HL146841 and U01HL156620-01), the Doris Duke Charitable Foundation (grant #2020147), the Mellon Foundation, Alexion, and the American Society of Hematology; has received consulting fees from Global Blood Therapeutics and Novo Nordisk; received support from the American Society of Hematology and the Hemostasis and Thrombosis Research Society for attending meetings; reports participation in a data safety monitoring board (CRESCENT [CRISPR SCD001]); and is the cofounder and vice chair of the Medical Advisory Board of the Sickle Cell Reproductive Health Education Directive, a member of the Maternal Health Working Group (American Society of Hematology), and cochair of the PhenX Genitourinary Working Group. The remaining authors declare no competing financial interests."

"This work was supported by Terumo Blood and Cell Technologies. Terumo Blood and Cell Technologies provided funding for conducting the study and for manuscript development but was not involved in creating the surveys or in interpreting the answers of the experts."